ICHORtec
Private Company
Funding information not available
Overview
ICHORtec is a private, early-stage biotech company pioneering a novel molecular interaction analysis platform. Its core innovation, Quantum-FMB®, directly measures thermodynamic energy changes (ΔG) via fluorescence photon analysis to quantify binding affinity and specificity with high accuracy. The company is leveraging this platform to develop point-of-care diagnostic kits (e.g., for MRSA, Tuberculosis) and provide contract research services, such as CRISPR gRNA nomination, aiming to improve precision in diagnostics and therapeutic development. ICHORtec appears to be in a pre-revenue or early-revenue stage, focusing on validating its technology and building its product portfolio.
Technology Platform
Quantum-FMB® platform that uses fluorescence photon analysis to directly measure Gibbs free energy changes (ΔG) during molecular binding events, providing thermodynamic specificity for applications in diagnostics and biomolecular characterization.
Opportunities
Risk Factors
Competitive Landscape
ICHORtec competes in the molecular diagnostics and life sciences tools markets against large, established players (e.g., Roche, Abbott, Thermo Fisher) offering PCR and immunoassay platforms, as well as numerous startups. Its differentiation hinges on the novel thermodynamic measurement approach of Quantum-FMB®, which must prove superior in specificity and utility to gain market share.